Legend Capital’s Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis
HONG KONG, Apr 27, 2022 – (ACN Newswire via SEAPRWire.com) – Legend Capital’s portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. Founded in 2017,... » read more